PAG Transparency information
Otsuka Pharma Scandinavia AB (OPSAB) is a subsidiary of Otsuka Pharmaceutical Europe Ltd (OPEL) who is a member of the national pharmaceutical industry associations in the Nordic region (Läkemedelsindustriföreningen (LIF), Legemiddelindustrien (LMI)) which incorporates the EFPIA disclosure code as part of the national codes in the Nordic region. As such Otsuka Pharma Scandinavia AB (OPSAB) agrees to publically disclose certain transfers of value made directly or indirectly to healthcare professionals and healthcare organisations. This includes, but is not limited to:
* The support provided by Otsuka is in no way intended as an inducement to prescribe, supply, recommend, buy or sell any products of Otsuka or any Otsuka group company, nor does Otsuka expect any favourable treatment by the institutions or any of their staff towards Otsuka personnel or representatives.
- Travel and accommodation
- Fee for services and all consultancy
- Any agreement related expenses or benefits (e.g. taxi, out of pocket expenses)
- Contribution towards events and costs of meetings paid to healthcare organisations
- Grants and donations
- Research and development (in aggregate)
- The publication of this data is necessary in order to comply with the transparency obligations arising from the EFPIA code
- Access to the website of Otsuka Pharmaceutical Europe Ltd or any of its affiliate companies does not grant any right to use the disclosed data for any purpose whatsoever.
- Otsuka Pharmaceutical Europe Ltd and its affiliates have taken reasonable steps in order to avoid indexation of the data on this website through public search engines.
Support to patient organisations and not-for-profit
Year | Country | External Stakeholder Group | Amount | Currency | Description |
2023 | Sweden | Schizofreniförbundet | 4572 | SEK | Panel discussion 2 - the patient perspective |
Sweden | Schizofreniförbundet | 30 000 | SEK | Workshop with "erfarenhetsgruppen" on Socialstyrelsen report on Schizophrenia guidelines | |
Sweden | Schizofreniförbundet | 4500 | SEK | Panel discussion 1 - the patient perspective | |
2022 | Belgium | AIRG (Association pour l’Information et la Recherche sur les maladies Rénales Génétiques) | 1000 | EUR | Annual patient meeting of AIRG |
2020 | Netherlands | Nier Patienten Vereniging (NVN) | 3000 | EUR | translation ADPKD routemap |
Belgium |
AIRG-Belgium |
4000 | EUR | the Annual day for Kidney Diseases | |
Netherlands | Nierpatienten Vereniging Nederlands | 6000 | EUR | A combination of a webinar and a physical meeting. We will invite keynote speakers and facilitate exchange of experiences among patients. We are planning to rent a corona-proof venue and arrange a studio to record the webinar for those patients who are unable to physically participate. | |
Sweden | Schizofreniförbundet | 70 000 | SEK | Printing of brochure re. mental illness | |
Denmark | Skizofreniforeningen | 35,000 | DKK | Nordic meeting with focus on severe mental illness | |
2019 | Nordic meeting held in Sweden | Skizofreniforeningen DK | 7,400 | DKK | To support for a Nordic collaboration between PAGs |
Nordic meeting held in Sweden where Finnish, Norwegian PAG attendees where present | Schizofreniföreningen SE | 26,325 | SEK | To support for a Nordic collaboration between PAGs |